The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ARMP | +162.27% | +103.89% | +15.3% | +24% |
| S&P | +13.43% | +88.37% | +13.49% | +140% |
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company was founded on May 9, 2019 and is headquartered in Los Angeles, CA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $1.16M | -61.0% |
| Gross Profit | $0.79M | -70.5% |
| Gross Margin | 68.08% | -21.8% |
| Market Cap | $107.96M | 25.9% |
| Market Cap / Employee | $1.80M | 0.0% |
| Employees | 60 | -9.1% |
| Net Income | -$26.68M | -386.7% |
| EBITDA | -$7.41M | 21.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $14.76M | -13.9% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $42.08M | 50.7% |
| Short Term Debt | $135.61M | 20.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -49.96% | -10.8% |
| Return On Invested Capital | -61.57% | 13.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$4.54M | 50.7% |
| Operating Free Cash Flow | -$4.30M | 51.5% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -1.31 | -1.10 | -1.28 | -1.55 | -16.51% |
| Price to Sales | 21.13 | 11.24 | 10.01 | 21.36 | 36.19% |
| Price to Tangible Book Value | -1.03 | -0.86 | -1.02 | -1.30 | -9.51% |
| Enterprise Value to EBITDA | -22.30 | -22.50 | -32.17 | -36.58 | 65.54% |
| Return on Equity | -3439.4% | - | |||
| Total Debt | $126.52M | $134.66M | $143.96M | $177.68M | 26.62% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
